PHASE-II STUDY OF INTRAPERITONEAL CISPLATIN PLUS SYSTEMIC ETOPOSIDE AS 2ND-LINE TREATMENT IN PATIENTS WITH SMALL-VOLUME RESIDUAL OVARIAN-CANCER

RS DEJONG; PHB WILLEMSE; EGE DEVRIES; WTA VANDERGRAAF; DT SLEIJFER; AGJ VANDERZEE; NH MULDER; J. Boonstra

PHASE-II STUDY OF INTRAPERITONEAL CISPLATIN PLUS SYSTEMIC ETOPOSIDE AS 2ND-LINE TREATMENT IN PATIENTS WITH SMALL-VOLUME RESIDUAL OVARIAN-CANCER

RS DEJONG, PHB WILLEMSE, EGE DEVRIES, WTA VANDERGRAAF, DT SLEIJFER, AGJ VANDERZEE, NH MULDER, J. Boonstra

Faculty of Medical Sciences/UMCG

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

The efficacy and toxicity of intraperitoneal (i.p.) cisplatin plus systemic etoposide were studied in 36 patients with small (

Original language	English
Pages (from-to)	709-713
Number of pages	5
Journal	European Journal of Cancer
Volume	31A
Issue number	5
Publication status	Published - 1995

Keywords

INTRAPERITONEAL CHEMOTHERAPY
ETOPOSIDE
CISPLATIN
OVARIAN CANCER
GYNECOLOGIC-ONCOLOGY-GROUP
THIOSULFATE PROTECTION
CHEMOTHERAPY
THERAPY
CARCINOMA
TRIAL
CARBOPLATIN
DISEASE
TUMORS
MICE

Handle.net

Persistent link

Cite this

@article{e7d5157180ab4545b04efc50e6dae2c1,

title = "PHASE-II STUDY OF INTRAPERITONEAL CISPLATIN PLUS SYSTEMIC ETOPOSIDE AS 2ND-LINE TREATMENT IN PATIENTS WITH SMALL-VOLUME RESIDUAL OVARIAN-CANCER",

abstract = "The efficacy and toxicity of intraperitoneal (i.p.) cisplatin plus systemic etoposide were studied in 36 patients with small (",

keywords = "INTRAPERITONEAL CHEMOTHERAPY, ETOPOSIDE, CISPLATIN, OVARIAN CANCER, GYNECOLOGIC-ONCOLOGY-GROUP, THIOSULFATE PROTECTION, CHEMOTHERAPY, THERAPY, CARCINOMA, TRIAL, CARBOPLATIN, DISEASE, TUMORS, MICE",

author = "RS DEJONG and PHB WILLEMSE and EGE DEVRIES and WTA VANDERGRAAF and DT SLEIJFER and AGJ VANDERZEE and NH MULDER and J. Boonstra",

year = "1995",

language = "English",

volume = "31A",

pages = "709--713",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "ELSEVIER SCI LTD",

number = "5",

}

TY - JOUR

T1 - PHASE-II STUDY OF INTRAPERITONEAL CISPLATIN PLUS SYSTEMIC ETOPOSIDE AS 2ND-LINE TREATMENT IN PATIENTS WITH SMALL-VOLUME RESIDUAL OVARIAN-CANCER

AU - DEJONG, RS

AU - WILLEMSE, PHB

AU - DEVRIES, EGE

AU - VANDERGRAAF, WTA

AU - SLEIJFER, DT

AU - VANDERZEE, AGJ

AU - MULDER, NH

AU - Boonstra, J.

PY - 1995

Y1 - 1995

N2 - The efficacy and toxicity of intraperitoneal (i.p.) cisplatin plus systemic etoposide were studied in 36 patients with small (

AB - The efficacy and toxicity of intraperitoneal (i.p.) cisplatin plus systemic etoposide were studied in 36 patients with small (

KW - INTRAPERITONEAL CHEMOTHERAPY

KW - ETOPOSIDE

KW - CISPLATIN

KW - OVARIAN CANCER

KW - GYNECOLOGIC-ONCOLOGY-GROUP

KW - THIOSULFATE PROTECTION

KW - CHEMOTHERAPY

KW - THERAPY

KW - CARCINOMA

KW - TRIAL

KW - CARBOPLATIN

KW - DISEASE

KW - TUMORS

KW - MICE

M3 - Article

SN - 0959-8049

VL - 31A

SP - 709

EP - 713

JO - European Journal of Cancer

JF - European Journal of Cancer

IS - 5

ER -

PHASE-II STUDY OF INTRAPERITONEAL CISPLATIN PLUS SYSTEMIC ETOPOSIDE AS 2ND-LINE TREATMENT IN PATIENTS WITH SMALL-VOLUME RESIDUAL OVARIAN-CANCER

Abstract

Keywords

Handle.net

Fingerprint

Cite this